NCT05267106 2025-12-30
FIGHT-209
Incyte Corporation
Phase 2 Terminated
Clinical Trials
6 trialsNCT03822117 2025-11-04
Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Incyte Corporation
Phase 2 Terminated
NCT04003610 2025-11-04
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
Incyte Corporation
Phase 2 Terminated
NCT03656536 2025-08-24
FIGHT-302
Incyte Corporation
Phase 3 Terminated
NCT04949191 2024-09-19
The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.
Incyte Corporation
Phase 2 Terminated
NCT04003623 2022-05-10
Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)
Incyte Corporation
Phase 2 Terminated